The European Commission has approved Tryngolza (olezarsen) for use in the European Union (EU) as an adjunct to diet in adult patients with genetically confirmed familial chylomicronaemia syndrome (FCS). The approval is based on positive data from the Phase 3 Balance study, in which olezarsen 80 mg significantly reduced fasting TG levels at six months, and was associated with a reduction in acute pancreatitis at week 53.1
